Amitiza lubiprostone: Phase III started

Sucampo began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 24 µg of oral lubiprostone given twice daily for 28 days in about 116 patients. The trial start triggers a $7.5 m...